SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (631)3/24/2004 8:41:45 AM
From: nigel bates  Read Replies (1) | Respond to of 1022
 
Amgen seems to have put some emphasis on AMG 162 in its recent presentation.

Any idea whose mAB (AMG 162 is a fully human monoclonal antibody that specifically and with high affinity binds and neutralizes RANKL...) it is ?

(Is it from Immunex/CAT, or Amgen/ABGX ?)